arrow
L

Lorenza Rimassa

Humanitas University
H指数:70
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-Derived Organoids from cryopreserved tissue can represent clinically relevant tools for drug testing in Biliary Cancer

源自冷冻保存组织的患者衍生物类器官可作为胆道癌药物测试的临床相关工具

2026-10-260
OAAI
Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores

在采用阿替利珠单抗/贝伐珠单抗治疗的肝癌患者中分层心血管风险:ESC评分与CARDIOSOR评分的比较

2026-10-070
OAAI
First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study

一线度伐利尤单抗和特瑞普利单抗在预后不良的不可切除肝细胞癌中的应用:IIIb期单臂SIERRA研究

2026-10-060
OAAI
Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab

早期肝功能失代偿与接受阿替利珠单抗联合贝伐珠单抗或度伐利尤单抗联合特瑞普利单抗治疗的HCC患者死亡率相关

2026-09-070
PRE
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma

肝病学:MASLD、病毒性肝炎、胆汁淤积性肝病、门静脉高压和肝细胞癌的新兴范式

2026-08-300
PRE
Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501)

切除后胆道癌的辅助化疗方案:国家性、比较性、观察性研究(TOG/GI-SAFRADJU-2501)

2026-08-150
OAAI
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)

在癌症患者的多学科管理中计算机断层扫描的请求和报告模型:意大利医学和介入放射学会(SIRM)与意大利医学肿瘤学会(AIOM)的共识

2026-07-070
OAAI
IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers

IDH1 R132突变或HER2阳性与胆道癌对铂类为基础的疗法的获益

2026-05-200
OAAI
Vessels Encapsulating Tumor Clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab

包裹肿瘤簇的血管可预测接受阿替利珠单抗–贝伐珠单抗治疗的晚期肝细胞癌的更好预后

2026-04-290
OAAI
Cholangiocarcinoma 2026: status quo, unmet needs and priorities

胆管癌2026: 现状,未满足的需求和优先事项

2025-12-100
OAAI
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

IIIb期SIERRA研究早期安全性结果:度伐利尤单抗和特瑞普利单抗作为不可切除肝细胞癌且预后不良患者的一线治疗方案。

2025-12-010
OA
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI